📊 NTLA Key Takeaways
Is NTLA a Good Investment? Thesis Analysis
Intellia is a pre-revenue CRISPR therapeutics company with severe cash burn (-$395.9M free cash flow) and negative profitability across all metrics, indicating the company is in early-stage development with substantial execution risk. While the company maintains adequate liquidity ($155.5M cash) relative to current burn rate, the fundamental business model is not yet profitable and depends entirely on successful clinical trial outcomes and regulatory approval.
Why Buy NTLA? Key Strengths
- Strong balance sheet with $671.4M stockholders equity and minimal debt
- Adequate liquidity position with $155.5M cash and 5.08x current ratio providing runway
- Revenue growth of 16.9% YoY demonstrates some commercial traction despite pre-commercial stage
NTLA Investment Risks to Consider
- Massive operating losses (-$441M) with operating margin of -651.7% indicate unsustainable business model dependent on R&D spending
- Severe negative free cash flow (-$395.9M) will deplete cash reserves within ~4 quarters at current burn rate without additional financing
- Clinical-stage biotech with existential risk tied to regulatory approval and clinical trial success; no approved products generating meaningful revenue
- Negative ROE (-61.5%) and ROA (-49.0%) reflect capital inefficiency and lack of profitability foundation
Key Metrics to Watch
- Operating cash flow trend and cash runway (critical for survival)
- Clinical trial progress and regulatory milestones for lead CRISPR programs
- Revenue growth rate and pipeline advancement toward commercialization
- Dilution from future financing rounds and impact on capital structure
NTLA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.08x current ratio provides a solid financial cushion.
NTLA Profitability Ratios
NTLA vs Default Sector
How Intellia Therapeutics, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NTLA Overvalued or Undervalued?
Based on fundamental analysis, Intellia Therapeutics, Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NTLA Balance Sheet & Liquidity
NTLA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Intellia Therapeutics, Inc.'s revenue has grown significantly by 17% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.42 indicates the company is currently unprofitable.
NTLA Growth Metrics (YoY)
NTLA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.1M | -$101.3M | $-0.92 |
| Q2 2025 | $7.0M | -$101.3M | $-0.98 |
| Q1 2025 | $16.6M | -$107.4M | $-1.10 |
| Q3 2024 | $9.1M | -$103.1M | $-1.34 |
| Q2 2024 | $7.0M | -$103.1M | $-1.40 |
| Q1 2024 | $12.6M | -$103.1M | $-1.12 |
| Q3 2023 | $12.0M | -$100.7M | $-1.38 |
| Q2 2023 | $13.6M | -$100.7M | $-1.33 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NTLA Capital Allocation
NTLA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Intellia Therapeutics, Inc. (CIK: 0001652130)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NTLA
What is the AI rating for NTLA?
Intellia Therapeutics, Inc. (NTLA) has an AI rating of SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NTLA's key strengths?
Claude: Strong balance sheet with $671.4M stockholders equity and minimal debt. Adequate liquidity position with $155.5M cash and 5.08x current ratio providing runway.
What are the risks of investing in NTLA?
Claude: Massive operating losses (-$441M) with operating margin of -651.7% indicate unsustainable business model dependent on R&D spending. Severe negative free cash flow (-$395.9M) will deplete cash reserves within ~4 quarters at current burn rate without additional financing.
What is NTLA's revenue and growth?
Intellia Therapeutics, Inc. reported revenue of $67.7M.
Does NTLA pay dividends?
Intellia Therapeutics, Inc. does not currently pay dividends.
Where can I find NTLA SEC filings?
Official SEC filings for Intellia Therapeutics, Inc. (CIK: 0001652130) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NTLA's EPS?
Intellia Therapeutics, Inc. has a diluted EPS of $-3.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NTLA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Intellia Therapeutics, Inc. has a SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NTLA stock overvalued or undervalued?
Valuation metrics for NTLA: ROE of -61.5% (sector avg: 15%), net margin of -609.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NTLA stock in 2026?
Our dual AI analysis gives Intellia Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NTLA's free cash flow?
Intellia Therapeutics, Inc.'s operating cash flow is $-394.7M, with capital expenditures of $1.1M. FCF margin is -585.0%.
How does NTLA compare to other Default stocks?
Vs Default sector averages: Net margin -609.9% (avg: 12%), ROE -61.5% (avg: 15%), current ratio 5.08 (avg: 1.8).